IRC
HRTX icon

Investors Research Corp’s Heron Therapeutics HRTX Stock Holding History

Investors Research Corp’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30
Closed -$45 – 1102
2023
Q1 		$45 Hold
30
– – ﹤0.01% 1110
2022
Q4 		$75 Hold
30
– – ﹤0.01% 1121
2022
Q3 		$0 Hold
30
– – ﹤0.01% 1110
2022
Q2 		$0 Hold
30
– – ﹤0.01% 1112
2022
Q1 		$0 Hold
30
– – ﹤0.01% 1054
2021
Q4 		$0 Hold
30
– – ﹤0.01% 1015
2021
Q3 		$0 Hold
30
– – ﹤0.01% 1011
2021
Q2 		$0 Hold
30
– – ﹤0.01% 991
2021
Q1 		$0 Hold
30
– – ﹤0.01% 1008
2020
Q4 		$1K Hold
30
– – ﹤0.01% 1031
2020
Q3 		$0 Buy
+30
New +$468 ﹤0.01% 1106

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Investors Research Corp's HRTX Position: Q2 2023 in Review

Investors Research Corp sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 30 shares — an estimated $45 sold.

Investors Research Corp first reported a position in HRTX in Q3 2020 and held it in 11 quarters. The position peaked at $1K in Q4 2020. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Investors Research Corp reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Investors Research Corp sold 30 Heron Therapeutics shares in Q2 2023, an estimated $45.
  • Investors Research Corp first reported a position in Heron Therapeutics in Q3 2020 and held it in 11 quarters.
  • Investors Research Corp's Heron Therapeutics position peaked at $1K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Investors Research Corp's 13F filing for Q2 2023, filed 14 Aug 2023.